


## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1-~~10~~<sup>9</sup> (Canceled).

Claim ~~11~~<sup>10</sup>. (New) A method of treating a functional motility disorder of the viscera in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I



in free form or in the form of a pharmaceutically acceptable salt, wherein

R<sup>1</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;


R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>7</sub>-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>4</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim ~~12~~<sup>11</sup>. (New) A method according to claim 1, in which the compound of formula I is of formula IA



where \* denotes the R configuration and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as defined in claim 1.

<sup>12</sup>  
Claim ~~13~~. (New) A method according to claim 1, in which

R<sup>1</sup> is phenyl, 3,5-bis(trifluoromethyl)-phenyl or 3,4,5-trimethoxyphenyl;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

<sup>13</sup>  
Claim ~~14~~. (New) A method according to claim 2, in which

R<sup>1</sup> is phenyl, 3,5-bis(trifluoromethyl)-phenyl or 3,4,5-trimethoxyphenyl;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

<sup>14</sup>  
Claim ~~15~~. (New) A method according to claim 1, in which

R<sup>1</sup> is 3,5-bis(trifluoromethyl)-phenyl;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

<sup>15</sup>  
Claim ~~16~~. (New) A method according to claim 2, in which

R<sup>1</sup> is 3,5-bis(trifluoromethyl)-phenyl;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim <sup>16</sup>~~17~~. (New) A method according to claim 1, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim <sup>17</sup>~~18~~. (New) A method according to claim 2, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim <sup>18</sup>~~19~~. (New) A method according to claim 1, in which the compound of formula I is selected from the group consisting of:

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-(N'-methyl-N'-benzoyl-amino)-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-(N'-methyl-N'-benzoyl)-amino-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,4,5-trimethoxy-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-cyclohexylamide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-2-methyl-but-2-enoic acid [(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-ethyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-3-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-3-methyl-but-2-enoic acid [(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3-fluoro-4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dibromobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4,5-trifluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-fluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,


(4R)- and (4S)-[N'-(3,5-bistrifluoromethyl-benzoyl)-N'-methyl-amino]-5,5-diphenyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide, and

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide.

Claim<sup>19</sup>~~20~~. (New) A method according to claim 1, in which the compound of formula I is a compound of formula II



Claim<sup>20</sup>~~21~~. (New) A method according to claim 1, in which the functional motility disorder is associated with visceral hypersensitivity or altered motor responses.

Claim<sup>21</sup>~~22~~. (New) A method according to claim 2, in which the functional motility disorder is a functional bowel disorder or a functional gastrointestinal disorder.

Claim<sup>22</sup>~~23~~. (New) A method according to claim 1, in which the functional motility disorder is irritable bowel syndrome or functional dyspepsia.

Claim<sup>23</sup>~~24~~. (New) A method according to claim 2, in which the functional motility disorder is irritable bowel syndrome or functional dyspepsia.

Claim<sup>24</sup>~~25~~. (New) A method according to claim 10, in which the functional motility disorder is irritable bowel syndrome or functional dyspepsia.

Claim<sup>25</sup>~~26~~. (New) A method according to claim 1, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim<sup>26</sup>~~27~~. (New) A method according to claim 10, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim<sup>27</sup>~~28~~. (New) A method according to claim 1, wherein the effective amount of the compound of formula I is from 1 mg to 1000 mg.

Claim<sup>28</sup>~~29~~. (New) A method according to claim 1, wherein the effective amount of the compound of formula I is from 5 mg to 200 mg.

Claim<sup>29</sup>~~30~~. (New) A method according to claim 10, wherein the effective amount of the compound of formula IA is from 1 mg to 1000 mg.